Abstract | BACKGROUND: METHODS: A total of 93 patients with previously untreated symptomatic MM were enrolled in this single-center study. In group-1, 40 patients received bortezomib 1.6 mg/m2 and dexamethasone 40 mg on days 1, 6 and 11, plus thalidomide 100 mg on days 1-21 (VTD-1). In group-2, 53 patients received bortezomib 1.3 mg/m2 and dexamethasone 40 mg on days 1, 4, 8 and 11 in combination with thalidomide 100 mg on days 1-21 (VTD-2). RESULTS: The odds ratio rates after 2 cycles of VTD and the best response during this study were 95% vs. 81.1% (P=0.044), and 95% vs. 90.6% (P=0.349) in group-1 and group-2, respectively. The best CR rate in group-1 was higher than that in group-2 [52.5% vs. 45.3% (P=0.316)]. In group-1, only 2 of 21 patients who achieved CR relapsed from the disease, as did 9 of 24 patients in group-2 (P=0.031). The median PFS in group-1 and group-2 were 34 and 28.8 months (P=0.969), and the median OS in group-1 and group-2 were 33.5 and 46.4 months (P=0.987). In group-1 and group-2, the median CD34+ cells of stem cell collection were 3.68×106 vs. 5.84×106 cells/kg (P=0.179). Patients in group-1 had a lower incidence of peripheral neuropathy than group-2 [32.5% vs. 41.5% (P=0.371)]. CONCLUSIONS:
|
Authors | Peipei Xu, Rongfu Zhou, Jingyan Xu, Jian Ouyang, Xiaoyan Shao, Bing Chen |
Journal | Translational cancer research
(Transl Cancer Res)
Vol. 8
Issue 5
Pg. 2099-2106
(Sep 2019)
ISSN: 2219-6803 [Electronic] China |
PMID | 35116959
(Publication Type: Journal Article)
|
Copyright | 2019 Translational Cancer Research. All rights reserved. |